Dogwood Therapeutics Announces Completion Of 239-Patient Enrollment In Phase 2b Halneuron Trial For Chemotherapy Induced Neuropathic Pain; Topline Data Expected November 2026

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Comments

No comments yet. Be the first!